Share-based Payment Arrangement, Expense of Summit Therapeutics Inc. from 31 Jan 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Summit Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Jan 2018 to 30 Sep 2025.
  • Summit Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $130,761,000, a 575% increase year-over-year.
  • Summit Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $631,656,000, a 1197% increase year-over-year.
  • Summit Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $50,981,000, a 261% increase from 2023.
  • Summit Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14,108,000, a 18% increase from 2022.
  • Summit Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $11,948,000, a 6.7% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Summit Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $631,656,000 $130,761,000 +$111,390,000 +575% 01 Jul 2025 30 Sep 2025 10-Q 20 Oct 2025 2025 Q3
Q2 2025 $520,266,000 $478,784,000 +$467,696,000 +4218% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $52,570,000 $11,096,000 +$1,589,000 +17% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $50,981,000 $11,015,000 +$2,262,000 +26% 01 Oct 2024 31 Dec 2024 10-K 24 Feb 2025 2024 FY
Q3 2024 $48,719,000 $19,371,000 +$18,666,000 +2648% 01 Jul 2024 30 Sep 2024 10-Q 20 Oct 2025 2025 Q3
Q2 2024 $30,053,000 $11,088,000 +$9,213,000 +491% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $20,840,000 $9,507,000 +$6,732,000 +243% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $14,108,000 $8,753,000 +$6,095,000 +229% 01 Oct 2023 31 Dec 2023 10-K 24 Feb 2025 2024 FY
Q3 2023 $8,013,000 $705,000 -$2,093,000 -75% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $10,106,000 $1,875,000 -$621,000 -25% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $10,727,000 $2,775,000 -$1,221,000 -31% 01 Jan 2023 31 Mar 2023 10-Q 01 May 2024 2024 Q1
Q4 2022 $11,948,000 $2,658,000 -$2,962,000 -53% 01 Oct 2022 31 Dec 2022 10-K 24 Feb 2025 2024 FY
Q3 2022 $14,910,000 $2,798,000 +$154,000 +5.8% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $14,756,000 $2,496,000 -$1,175,000 -32% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $15,931,000 $3,996,000 +$3,127,000 +360% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $12,804,000 $5,620,000 +$5,042,000 +872% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $7,762,000 $2,644,000 +$2,283,000 +632% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $5,479,000 $3,671,000 +$3,141,000 +593% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $2,338,000 $869,000 +$572,000 +193% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $1,766,000 $578,000 01 Oct 2020 31 Dec 2020 10-K/A 21 Dec 2022 2021 FY
Q3 2020 $361,000 +$117,000 +48% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $530,000 +$266,000 +101% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $297,000 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q3 2019 $244,000 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $264,000 01 Apr 2019 30 Jun 2019 8-K 29 Sep 2020 2020 Q2

Summit Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $50,981,000 +$36,873,000 +261% 01 Jan 2024 31 Dec 2024 10-K 24 Feb 2025 2024 FY
2023 $14,108,000 +$2,160,000 +18% 01 Jan 2023 31 Dec 2023 10-K 24 Feb 2025 2024 FY
2022 $11,948,000 -$856,000 -6.7% 01 Jan 2022 31 Dec 2022 10-K 24 Feb 2025 2024 FY
2021 $12,804,000 +$11,038,000 +625% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $1,766,000 +$921,000 +109% 01 Jan 2020 31 Dec 2020 10-K/A 21 Dec 2022 2021 FY
2019 $845,000 -$5,450,000 -87% 01 Feb 2019 31 Dec 2019 10-K 31 Mar 2021 2020 FY
2018 $6,295,000 +$4,204,000 +201% 01 Feb 2018 31 Jan 2019 10-K 31 Mar 2021 2020 FY
2017 $2,091,000 01 Feb 2017 31 Jan 2018 8-K 29 Sep 2020 2020 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.